Piramal Pharma Digwal Facility US FDA Inspection Closed

Piramal Pharma received an Establishment Inspection Report from the US FDA for its Digwal, Telangana manufacturing facility.
The US FDA inspection, initiated in February 2026, has been successfully closed with no observations cited.
This disclosure is a regulatory requirement under SEBI Listing Regulations submitted on the first working day after EIR receipt.